503A Price Audit Verified: Semaglutide $49/mo · Tirzepatide $99/mo ($0 Platform Membership · All Doses Locked) Claim $49 Rate →
Losing Weight RX Open-Data Desk
Zero-Dependency Pharmacoeconomic Tool · Powered by DOI 10.5281/zenodo.24139315

Standard 503A Vial Concentration (mg/mL) to U-100 Syringe Units Reference Verifier (2026)

Educational pharmacy-label reference table verifying how standard 2.5 mg/mL, 5 mg/mL, 10 mg/mL, and 20 mg/mL 503A concentrations map to U-100 insulin syringe graduations.

IMPORTANT CLINICAL & PHARMACY LABEL VERIFICATION NOTICE

This reference displays standard arithmetic conversions (Units = (Dose mg ÷ Concentration mg/mL) × 100) for educational label literacy only. Compounded vial concentrations vary by pharmacy. Always follow the exact unit instructions printed on your prescription vial label and consult your licensed prescriber or pharmacist before administering any medication.

U-100 Syringe Graduation
48 Units
Liquid Volume Drawn
0.48 mL
28-Day Cumulative Active API
9.60 mg

Underlying Empirical Dataset Citation

All default provider rates, PBM thresholds, and bioavailability coefficients in this tool are drawn directly from our open-access CC-BY-4.0 dataset (glp1-dose-titration-cost-per-mg-yield-2026 · Academic DOI 10.5281/zenodo.24139315).

Ready to Lock In Your Verified Flat Rate?

$0 platform membership, $0 high-dose escalation surcharges, and free express cold-chain shipping.

Get Clinician-Guided 503A Dosing ($49/mo) →

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in Standard 503A Vial Concentration (mg/mL) to U-100 Syringe Units Reference Verifier (2026) is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Billings, L. K., Winne, L., Sharma, P., Gomez-Valderas, E., Chivukula, K. K., & Kwan, A. Y. M. (2025). Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial. Annals of internal medicine, 178(5), 609-619. https://doi.org/10.7326/ANNALS-24-03849
  2. DailyMed, National Library of Medicine. (2025). Semaglutide drug label search. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=semaglutide
  3. Harvard Health Publishing, Harvard Medical School. (2024). How does Ozempic work? Understanding GLP-1s for diabetes, weight loss, and beyond. https://www.health.harvard.edu/staying-healthy/how-does-ozempic-work-understanding-glp-1s-for-diabetes-weight-loss-and-beyond
  4. O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet (London, England), 392(10148), 637-649. https://doi.org/10.1016/S0140-6736(18)31773-2
  5. Samuels, J. M., Ye, F., Irlmeier, R., Silver, H., Srivastava, G., & Spann, M. (2025). Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic. Diabetes, obesity & metabolism, 27(11), 6200-6209. https://doi.org/10.1111/dom.70004
  6. U.S. Food and Drug Administration. (2023). Ozempic (semaglutide) injection, for subcutaneous use: Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf